KRAS and cancer: This drug is specifically designed for patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation and functions by inhibiting the activity of the KRAS G12C protein, thereby impacting the growth and metabolism of cancer cells 204.